Interleukin (IL)-15 in combination with IL-2, fms-like tyrosine kinase-3 ligand and anti-CD3 significantly enhances umbilical cord blood natural killer (NK) cell and NK-cell subset expansion and NK function

Cytotherapy

Volumn 13, Issue 6, 2011, Pages 730-738

  Satwani, Prakash ^a   Van De Ven, Carmella ^a   Ayello, Janet ^a   Cairo, Dustin ^a   Simpson, Lynn L ^a   Baxi, Laxmi ^a   Cairo, Mitchell S ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NewYork Presbyterian Hospital   (United States)

Author keywords

cord blood; cytokines; natural killer cells

Indexed keywords

CD135 ANTIGEN; CD3 ANTIBODY; EUROPIUM; INTERLEUKIN 15; INTERLEUKIN 2; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MONOCLONAL ANTIBODY;

ARTICLE; CELL ASSAY; CELL CULTURE; CELL EXPANSION; CELL FUNCTION; CELL POPULATION; CELL STRAIN K 562; CULTURE MEDIUM; CYTOTOXICITY; DAUDI CELL; FLOW CYTOMETRY; FLUORESCENCE; IN VITRO STUDY; LYMPHOKINE ACTIVATED KILLER CELL; MONONUCLEAR CELL; NATURAL KILLER CELL; PRIORITY JOURNAL; UMBILICAL CORD BLOOD;

EID: 79959241846     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.3109/14653249.2011.563292     Document Type: Article

References (44)

1. Cairo MS, Wagner JE. Placental and/or umbilical cord blood: an alternative source of hematopoietic stem cells for transplantation. Blood. 1997;90:4665-78. (Pubitemid 28007178)
2. Gluckman E, Rocha V, Boyer-Chammard A, Locatelli F, Arcese W, Pasquini R, et al. Outcome of cord-blood transplantation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. New Engl J Med. 1997;337:373-81.
3. Kurtzberg J, Laughlin M, Graham ML, Smith C, Olson JF, Halperin EC, et al. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. New Engl J Med. 1996;335:157-66. (Pubitemid 26249452)
4. Laughlin MJ, Barker J, Bambach B, Koc ON, Rizzieri DA, Wagner JE, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. New Engl J Med. 2001;344:1815-22. (Pubitemid 32538694)
5. Robinson KL, Ayello J, Hughes R, van de Ven C, Issitt L, Kurtzberg J, et al. Ex vivo expansion, maturation, and activation of umbilical cord blood-derived T lymphocytes with IL-2, IL-12, anti-CD3, and IL-7. Potential for adoptive cellular immunotherapy post-umbilical cord blood transplantation. Exp Hematol. 2002;30:245-51.
6. Rocha V, Wagner JE Jr, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM, et al. Graft-versus-host disease in children who have received a cord-blood or bone marrow transplant from an HLA-identical sibling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. New Engl J Med. 2000;342:1846-54. (Pubitemid 30419048)
7. Wagner JE, Rosenthal J, Sweetman R, Shu XO, Davies SM, Ramsay NK, et al. Successful transplantation of HLAmatched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graftversus- host disease. Blood. 1996;88:795-802. (Pubitemid 26333297)
8. Abu-Ghosh A, Goldman S, Slone V, van de Ven C, Suen Y, Murphy L, et al. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation. Bone Marrow Transplant. 1999;24:535-44. (Pubitemid 29423634)
9. Giraud P, Thuret I, Reviron D, Chambost H, Brunet C, Novakovitch G, et al. Immune reconstitution and outcome after unrelated cord blood transplantation: a single paediatric institution experience. Bone Marrow Transplant. 2000;25:53-7. (Pubitemid 30093156)
10. Moretta A, Maccario R, Fagioli F, Giraldi E, Busca A, Montagna D, et al. Analysis of immune reconstitution in children undergoing cord blood transplantation. Exp Hematol. 2001;29:371-9. (Pubitemid 32220129)
11. Rubinstein P, Carrier C, Scaradavou A, Kurtzberg J, Adamson J, Migliaccio AR, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. New Engl J Med. 1998;339:1565-77. (Pubitemid 28536131)
12. Szabolcs P, Cairo MS. Unrelated umbilical cord blood transplantation and immune reconstitution. Sem Hematol. 2010;47:22-36.
13. Thompson JA, Gilliland DG, Prchal JT, Bennett JM, Larholt K, Nelson RA, et al. Effect of recombinant human erythropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood. 2000;95:1175-9.
14. Harris DT, LoCascio J, Besencon FJ. Analysis of the alloreactive capacity of human umbilical cord blood: implications for graft-versus-host disease. Bone Marrow Transplant. 1994; 14:545-53. (Pubitemid 24338479)
15. Harris DT, Schumacher MJ, Locascio J, Besencon FJ, Olson GB, DeLuca D, et al. Phenotypic and functional immaturity of human umbilical cord blood T lymphocytes. Proc Natl Acad Sci USA. 1992;89:10006-10.
16. Risdon G, Gaddy J, Horie M, Broxmeyer HE. Alloantigen priming induces a state of unresponsiveness in human umbilical cord blood T cells. Proc Natl Acad Sci USA. 1995;92: 2413-7.
17. Risdon G, Gaddy J, Stehman FB, Broxmeyer HE. Proliferative and cytotoxic responses of human cord blood T lymphocytes following allogeneic stimulation. Cell Immunol. 1994;154:14-24. (Pubitemid 24084413)
18. Lee SM, Suen Y, Chang L, Bruner V, Qian J, Indes J, et al. Decreased interleukin-12 (IL-12) from activated cord versus adult peripheral blood mononuclear cells and upregulation of interferon-gamma, natural killer, and lymphokine-activated killer activity by IL-12 in cord blood mononuclear cells. Blood. 1996;88:945-54.
19. Qian JX, Lee SM, Suen Y, Knoppel E, van de Ven C, Cairo MS. Decreased interleukin-15 from activated cord versus adult peripheral blood mononuclear cells and the effect of interleukin-15 in upregulating antitumor immune activity and cytokine production in cord blood. Blood. 1997;90: 3106-17. (Pubitemid 27444205)
20. Carson WE, Ross ME, Baiocchi RA, Marien MJ, Boiani N, Grabstein K, et al. Endogenous production of interleukin 15 by activated human monocytes is critical for optimal production of interferon-gamma by natural killer cells in vitro. J Clin Invest. 1995;96:2578-82.
21. Doherty TM, Seder RA, Sher A. Induction and regulation of IL-15 expression in murine macrophages. J Immunol. 1996; 156:735-41. (Pubitemid 26028932)
22. Carson WE, Giri JG, Lindemann MJ, Linett ML, Ahdieh M, Paxton R, et al. Interleukin (IL) 15 is a novel cytokine that activates human natural killer cells via components of the IL-2 receptor. J Exp Med. 1994;180:1395-403. (Pubitemid 24289613)
23. Fehniger TA, Caligiuri MA. Interleukin 15: biology and relevance to human disease. Blood. 2001;97:14-32. (Pubitemid 32061238)
24. Kennedy MK, Glaccum M, Brown SN, Butz EA, Viney JL, Embers M, et al. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med. 2000;191:771-80.
25. + hematopoietic progenitor cells. Blood. 1996; 87:2632-40.
26. Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, et al. Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood. 1998;92:3647-57. (Pubitemid 28525190)
27. Farag SS, Fehniger TA, Ruggeri L, Velardi A, Caligiuri MA. Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect. Blood. 2002;100:1935-47. (Pubitemid 35001221)
28. Moretta A, Bottino C, Vitale M, Pende D, Cantoni C, Mingari MC, et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Ann Rev Immunol. 2001;19:197-223. (Pubitemid 32368034)
29. Ayello J, van de Ven C, Cairo E, Hochberg J, Baxi L, Satwani P, et al. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy. Exp Hematol. 2009;37:1216-29.
30. Ayello J, van de Ven C, Fortino W, Wade-Harris C, Satwani P, Baxi L, et al. Characterization of cord blood natural killer and lymphokine activated killer lymphocytes following ex vivo cellular engineering. Biol Blood Marrow Transplant. 2006; 12:608-22.
31. Satwani P, Ayello J, Ven C, O' N eill AF, Simpson LL, Baxi L, et al. Immaturity of IL-18 gene expression and protein production in cord blood (CB) versus peripheral blood (PB) mononuclear cells and differential effects in natural killer (NK) cell development and function. Br J Haematol. 2005;130:284-92. (Pubitemid 41602530)
32. Miller JS, McCullar V. Human natural killer cells with polyclonal lectin and immunoglobulin like receptors develop from single hematopoietic stem cells with preferential expression of NKG2A and KIR2DL2/L3/S2. Blood. 2001;98:705-13.
33. Nagamura-Inoue T, Mori Y, Yizhou Z, Watanabe N, Takahashi TA. Differential expansion of umbilical cord blood mononuclear cell-derived natural killer cells dependent on the dose of interleukin-15 with Flt3L. Exp Hematol. 2004;32:202-9.
34. Ruggeri L, Capanni M, Urbani E, Perruccio K, Shlomchik WD, Tosti A, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science. 2002;295:2097-100. (Pubitemid 34229476)
35. Willemze R, Rodrigues CA, Labopin M, Sanz G, Michel G, Socie G, et al. KIR-ligand incompatibility in the graft-versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009; 23:492-500.
36. Vitale C, Chiossone L, Morreale G, Lanino E, Cottalasso F, Moretti S, et al. Analysis of the activating receptors and cytolytic function of human natural killer cells undergoing in vivo differentiation after allogeneic bone marrow transplantation. Eur J Immunol. 2004;34:455-60. (Pubitemid 39255956)
37. Cooley S, McCullar V, Wangen R, Bergemann TL, Spellman S, Weisdorf DJ, et al. KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation. Blood. 2005;106:4370-6. (Pubitemid 41775950)
38. Dunbar EM, Buzzeo MP, Levine JB, Schold JD, Meier- Kriesche HU, Reddy V. The relationship between circulating natural killer cells after reduced intensity conditioning hematopoietic stem cell transplantation and relapse-free survival and graft-versus-host disease. Haematologica. 2008;93: 1852-8.
39. Passweg JR, Stern M, Koehl U, Uharek L, Tichelli A. Use of natural killer cells in hematopoietic stem cell transplantation. Bone Marrow Transplant. 2005;35:637-43. (Pubitemid 40520947)
40. Passweg JR, Tichelli A, Meyer-Monard S, Heim D, Stern M, Kuhne T, et al. Purified donor NK-lymphocyte infusion to consolidate engraftment after haploidentical stem cell transplantation. Leukemia. 2004;18:1835-8. (Pubitemid 39530014)
41. Yoon SR, Lee YS, Yang SH, Ahn KH, Lee JH, Lee JH, et al. Generation of donor natural killer cells from CD34(+) progenitor cells and subsequent infusion after HLA-mismatched allogeneic hematopoietic cell transplantation: a feasibility study. Bone Marrow Transplant. 2010;45:1038-46.
42. Miller JS, Brunstein C, Cooley S, Verneris MR, Panoskaltsis- Mortari A, Burns LJ, et al. A novel triple umbilical cord blood transplant (UCBT) strategy to promote NK cell immunotherapy (Unit 1) with a fully ablative preparative regimen followed by a double UCBT in patients with refractory AML. Biol Blood Marrow Transplant. 2007;13:1403.
43. Berger C, Berger M, Hackman RC, Gough M, Elliott C, Jensen MC, et al. Safety and immunologic effects of IL-15 administration in nonhuman primates. Blood. 2009;114: 2417-26.
44. Chen W, Chan AS, Dawson AJ, Liang X, Blazar BR, Miller JS. FLT3 ligand administration after hematopoietic cell transplantation increases circulating dendritic cell precursors that can be activated by CpG oligodeoxynucleotides to enhance T-cell and natural killer cell function. Biol Blood Marrow Transplant. 2005;11:23-34. (Pubitemid 40057990)